NeoPharm Submits Application For A Multicenter, Open-Label, Phase II Study Of LE-DT For Castrate Resistant Prostate Cancer

NeoPharm Submits Application For A Multicenter, Open-Label, Phase II Study Of LE-DT For Castrate Resistant Prostate Cancer
NeoPharm, Inc. (NASDAQ: NEOL) announced that it has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, in hormone refractory metastatic prostate cancer patients. "The preliminary results from our Phase I trial, which has not yet concluded, have been encouraging.